{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T20:34:19Z","timestamp":1793651659521,"version":"4.5.1"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1097\/aog.0b013e318291718c","type":"journal-article","created":{"date-parts":[[2013,5,8]],"date-time":"2013-05-08T07:46:12Z","timestamp":1367999172000},"page":"1291-1299","source":"Crossref","is-referenced-by-count":121,"title":["Denosumab Compared With Ibandronate in Postmenopausal Women Previously Treated With Bisphosphonate Therapy"],"prefix":"10.1097","volume":"121","author":[{"given":"Chris","family":"Recknor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Czerwinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry G.","family":"Bone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sydney L.","family":"Bonnick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Binkley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santiago","family":"Palacios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfred","family":"Moffett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suresh","family":"Siddhanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prayashi","family":"Ghelani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel B.","family":"Wagman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesse W.","family":"Hall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Bolognese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claude-Laurent","family":"Benhamou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-21-20210126","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1001\/jama.285.6.785","article-title":"Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy.","volume":"285","year":"2001","journal-title":"JAMA"},{"key":"R2-21-20210126","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","article-title":". Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group.","volume":"348","author":"Black","year":"1996","journal-title":"Lancet"},{"key":"R3-21-20210126","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa031975","article-title":". The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis.","volume":"349","author":"Black","year":"2003","journal-title":"N Engl J Med"},{"key":"R4-21-20210126","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1001\/jama.280.24.2077","article-title":". Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial.","volume":"280","author":"Cummings","year":"1998","journal-title":"JAMA"},{"key":"R5-21-20210126","first-page":"1895","article-title":"Risedronate reverses bone loss in postmenopausal women with low bone mass: results from a multinational, double-blind, placebo-controlled trial. BMD-MN Study Group.","volume":"85","author":"Fogelman","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"R6-21-20210126","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","article-title":". Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group.","volume":"282","author":"Harris","year":"1999","journal-title":"JAMA"},{"key":"R7-21-20210126","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1016\/S0140-6736(06)68891-0","article-title":"Osteoporosis.","volume":"367","author":"Sambrook","year":"2006","journal-title":"Lancet"},{"key":"R8-21-20210126","doi-asserted-by":"crossref","first-page":"856","DOI":"10.4065\/80.7.856","article-title":"Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women.","volume":"80","author":"Recker","year":"2005","journal-title":"Mayo Clin Proc"},{"key":"R9-21-20210126","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.4065\/81.8.1013","article-title":". Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases.","volume":"81","author":"Siris","year":"2006","journal-title":"Mayo Clin Proc"},{"key":"R11-21-20210126","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.amjopharm.2008.12.002","article-title":"Osteoporosis pharmacotherapy and counseling services in US ambulatory care clinics: opportunities for multidisciplinary interventions.","volume":"6","author":"Teschemaker","year":"2008","journal-title":"Am J Geriatr Pharmacother"},{"key":"R12-21-20210126","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.bone.2007.03.011","article-title":". Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.","volume":"41","author":"McClung","year":"2007","journal-title":"Bone"},{"key":"R13-21-20210126","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1002\/jbmr.119","article-title":". Efficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study.","volume":"25","author":"Orwoll","year":"2010","journal-title":"J Bone Miner Res"},{"key":"R14-21-20210126","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S0002-9440(10)64556-7","article-title":". Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo.","volume":"157","author":"Lacey","year":"2000","journal-title":"Am J Pathol"},{"key":"R15-21-20210126","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0092-8674(00)81569-X","article-title":". Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.","volume":"93","author":"Lacey","year":"1998","journal-title":"Cell"},{"key":"R16-21-20210126","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1210\/endo.141.9.7634","article-title":". Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function.","volume":"141","author":"Udagawa","year":"2000","journal-title":"Endocrinology"},{"key":"R17-21-20210126","doi-asserted-by":"crossref","first-page":"3597","DOI":"10.1073\/pnas.95.7.3597","article-title":". Osteoclast differentiation factor is a ligand for osteoprotegerinosteoclastogenesis-inhibitory factor and is identical to TRANCERANKL.","volume":"95","author":"Yasuda","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R18-21-20210126","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":". Denosumab for prevention of fractures in postmenopausal women with osteoporosis.","volume":"361","author":"Cummings","year":"2009","journal-title":"N Engl J Med"},{"key":"R19-21-20210126","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1359\/jbmr.0809010","article-title":". Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial.","volume":"24","author":"Brown","year":"2009","journal-title":"J Bone Miner Res"},{"key":"R20-21-20210126","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1359\/jbmr.090716","article-title":". Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy.","volume":"25","author":"Kendler","year":"2010","journal-title":"J Bone Miner Res"},{"key":"R21-21-20210126","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1345\/aph.1Q652","article-title":". Psychometric properties of the osteoporosis-specific Morisky Medication Adherence Scale in postmenopausal women with osteoporosis newly treated with bisphosphonates.","volume":"46","author":"Reynolds","year":"2012","journal-title":"Ann Pharmacother"},{"key":"R22-21-20210126","doi-asserted-by":"crossref","first-page":"361","DOI":"10.2307\/2530862","article-title":"Testing for qualitative interactions between treatment effects and patient subsets.","volume":"41","author":"Gail","year":"1985","journal-title":"Biometrics"},{"key":"R23-21-20210126","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1385\/JCD:4:2:105","article-title":". Importance of precision in bone density measurements.","volume":"4","author":"Bonnick","year":"2001","journal-title":"J Clin Densitom"},{"key":"R24-21-20210126","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":". Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.","volume":"344","author":"Neer","year":"2001","journal-title":"N Engl J Med"},{"key":"R25-21-20210126","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/jbmr.1472","article-title":". Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures.","volume":"27","author":"Austin","year":"2012","journal-title":"J Bone Miner Res"},{"key":"R26-21-20210126","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1002\/jbmr.1479","article-title":". Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension.","volume":"27","author":"Papapoulos","year":"2012","journal-title":"J Bone Miner Res"},{"key":"R27-21-20210126","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/jbmr.1494","article-title":". The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT).","volume":"27","author":"Black","year":"2012","journal-title":"J Bone Miner Res"},{"key":"R28-21-20210126","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1001\/jama.296.24.2927","article-title":". Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial.","volume":"296","author":"Black","year":"2006","journal-title":"JAMA"},{"key":"R29-21-20210126","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa030897","article-title":". Ten years experience with alendronate for osteoporosis in postmenopausal women.","volume":"350","author":"Bone","year":"2004","journal-title":"N Engl J Med"},{"key":"R30-21-20210126","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1002\/jbmr.1570","article-title":". Postmenopausal osteoporosis treatment with antiresorptives: effects of discontinuation or long-term continuation on bone turnover and fracture risk-a perspective.","volume":"27","author":"Boonen","year":"2012","journal-title":"J Bone Miner Res"},{"key":"R31-21-20210126","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1002\/jbmr.251","article-title":". Effects of denosumab on bone turnover markers in postmenopausal osteoporosis.","volume":"26","author":"Eastell","year":"2011","journal-title":"J Bone Miner Res"},{"key":"R32-21-20210126","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.bone.2008.04.007","article-title":". Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial.","volume":"43","author":"Miller","year":"2008","journal-title":"Bone"},{"key":"R33-21-20210126","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1196\/annals.1402.089","article-title":". Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy.","volume":"1117","author":"Russell","year":"2007","journal-title":"Ann N Y Acad Sci"},{"key":"R34-21-20210126","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1007\/s11926-008-0021-x","article-title":"Compliance and persistence with osteoporosis therapies.","volume":"10","author":"Silverman","year":"2008","journal-title":"Curr Rheumatol Rep"},{"key":"R35-21-20210126","doi-asserted-by":"crossref","first-page":"728","DOI":"10.18553\/jmcp.2009.15.9.728","article-title":"Comparing adherence and persistence across 6 chronic medication classes.","volume":"15","author":"Yeaw","year":"2009","journal-title":"J Manag Care Pharm"},{"key":"R36-21-20210126","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s00198-011-1780-1","article-title":". Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women.","volume":"23","author":"Freemantle","year":"2012","journal-title":"Osteoporos Int"}],"container-title":["Obstetrics & Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/AOG.0b013e318291718c","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T18:54:24Z","timestamp":1620932064000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006250-201306000-00021"}},"subtitle":["A Randomized Open-Label Trial"],"short-title":[],"issued":{"date-parts":[[2013,6]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/aog.0b013e318291718c","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.718052095.793482005","asserted-by":"object"}]},"ISSN":["0029-7844"],"issn-type":[{"value":"0029-7844","type":"print"}],"subject":[],"published":{"date-parts":[[2013,6]]}}}